Drugs / HM10560A
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01093742 | Mar → Aug 2010 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01822340 | Oct 2011 → Jun 2015 | pituitary deficiency | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HM10560A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01822340 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Growth Hormone” NCT01822340 ↗ |
| Route | Subcutaneous | “Subcutaneously administrate at 0 hour on Day 1” NCT01093742 ↗ |